Loading stock data…
DNA
$9.70+1.24 (+14.66%)
Market ClosedLast close May 1
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ginkgo Bioworks Holdings, Inc. in the Healthcare sector is trading at $9.70. The stock is currently 45% below its 52-week high of $17.58, remaining 3.5% below its 200-day moving average. Technical signals show overbought RSI of 78 and bullish MACD crossover, explaining why DNA maintains its current current market pressure. The Whystock Score of 0/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 78) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.70
Potential Upside
5%
Whystock Fair Value$10.19
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and develop...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$522.64M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-61.50%
Volume
Today's trading volume
1.97M
Recent News
How The Ginkgo Bioworks (DNA) Story Is Shifting As Analysts Revisit Growth And Risk
Analysts have been trimming their price targets on Ginkgo Bioworks Holdings, with bullish views moving to about US$12 from US$14 and more cautious calls dropping to around US$5 from US$9. These shifts line up with a more mixed narrative, where some analysts still see long term potential, while others are more focused on execution risk and the impact of recent business changes. As you read on, you will see how to track these evolving views and what they might mean for your own research on the...
A Look At Ginkgo Bioworks (DNA) Valuation After Earnings Update And Invaio Collaboration
Why Ginkgo Bioworks is back on investors’ radar Ginkgo Bioworks Holdings (DNA) has drawn fresh attention after reporting full year 2025 results that paired lower sales with a smaller net loss, alongside a new collaboration with Invaio Sciences on peptide based crop protection. See our latest analysis for Ginkgo Bioworks Holdings. The earnings release and Invaio collaboration have landed against a tough backdrop, with Ginkgo Bioworks Holdings’ 1 day share price return of 30.48% decline at...
Ginkgo Bioworks Q4 Earnings Call Highlights
Ginkgo Bioworks (NYSE:DNA) used its fourth-quarter earnings call to outline a sharpened strategic focus for 2026 centered on “autonomous labs,” while also detailing year-over-year declines in cell engineering revenue and continued progress on expense reductions and cash burn. 2026 focus shifts towa
Ginkgo Bioworks Holdings Inc (DNA) Q4 2025 Earnings Call Highlights: Strategic Shifts and ...
Ginkgo Bioworks Holdings Inc (DNA) focuses on autonomous labs and cash burn reduction while navigating revenue declines and restructuring impacts.
Ginkgo Bioworks Holdings, Inc. Q4 2025 Earnings Call Summary
Moby summary of Ginkgo Bioworks Holdings, Inc.'s Q4 2025 earnings call